title: ALK positivity on pleuroscopic pleural biopsy in lung adenocarcinoma.
abstract: Lung cancer is the leading cause of cancer deaths worldwide, and around 75% to 80% of lung cancers are detected in advanced stage. Multiple genetic mutations are identified and reported in adenocarcinoma of the lung. Various pulmonary samples can be tested for molecular mutations in lung cancer. However, feasibility of molecular profiling of pleuroscopic pleural biopsies in lung adenocarcinoma is not reported. We describe a case of advanced adenocarcinoma of lung with positive anaplastic lymphoma tyrosine kinase mutation on pleuroscopic pleural biopsy and improved with oral crizotinib. The current case highlights the feasibility of pleuroscopy.-guided pleural biopsies in molecular profiling of lung adenocarcinoma.
authors.affiliation: Institute of Pulmonology, Medical Research and Development; Lung Care Team, Fortis Hospitals, Mumbai, Maharashtra, India.
authors.forename: Preyas J
authors.initials: PJ
authors.lastname: Vaidya
authors.affiliation: Institute of Pulmonology, Medical Research and Development; Lung Care Team, Fortis Hospitals, Mumbai, Maharashtra, India.
authors.forename: Arvind H
authors.initials: AH
authors.lastname: Kate
authors.affiliation: Institute of Pulmonology, Medical Research and Development; Lung Care Team, Fortis Hospitals, Mumbai, Maharashtra, India.
authors.forename: Deval
authors.initials: D
authors.lastname: Mehta
authors.affiliation: Department of Oncology, Fortis Hospital, Mulund, Mumbai, Maharashtra, India.
authors.forename: Boman N
authors.initials: BN
authors.lastname: Dhabar
authors.affiliation: Institute of Pulmonology, Medical Research and Development; Lung Care Team, Fortis Hospitals, Mumbai, Maharashtra, India.
authors.forename: Prashant N
authors.initials: PN
authors.lastname: Chhajed
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D000077192:Adenocarcinoma of Lung; D000077548:Anaplastic Lymphoma Kinase; D014408:Biomarkers, Tumor; D001706:Biopsy; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D008875:Middle Aged; D009154:Mutation; D010994:Pleura / Q000473:pathology*; D013902:Radiography, Thoracic; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics* / Q000378:metabolism; D020708:Thoracoscopes; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases